Unknown PHASE2 INTERVENTIONAL 1-arm NCT03153358

Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation

Icotinib Combined With Stereotactic Body Radiation Therapy (SBRT) for Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Sponsor: Sichuan Cancer Hospital and Research Institute

Conditions Lung Cancer Stage IV

Interventions Icotinib SBRT

Updated 6 times since 2017 Last updated: May 13, 2017 Started: Jun 2, 2017 Primary completion: Nov 2, 2017 Completion: May 2, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lung Cancer Stage IV, this trial is ongoing. The trial is conducted by Sichuan Cancer Hospital and Research Institute and has accumulated 6 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Jun 2019 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Jul 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sichuan Cancer Hospital and Research Institute

Data source: Sichuan Cancer Hospital and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.